Search Medical Condition
Please enter condition
Please choose location from dropdown

Pontedera, Italy Clinical Trials

A listing of Pontedera, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (8) clinical trials

CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer

Breast cancer is the most common form of cancer among women in North America, Europe and Latin America. Because nearly 80% of breast cancers are endocrine-responsive tumors, the majority of patients candidates for adjuvant chemotherapy (CT) are also candidates for endocrine therapy (ET). The optimal timing (i.e. concomitant vs sequential ...

Phase

0.0 miles

Learn More »

Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients

The search for prognostic and predictive factors that could influence the survival of patients treated for metastatic breast cancer has already been the subject of several studies. It seems that 2 components in the natural outcome of tumors must be considered. The first category is related to the primary characteristics ...

Phase

0.0 miles

Learn More »

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

In this study everolimus will be administered in combination with exemestane, which is an irreversible steroidal aromatase inactivator that has demonstrated efficacy in the treatment of postmenopausal patients with ABC. Exemestane is indicated for adjuvant treatment of postmenopausal women with HR+ EBC who have received two to three years of ...

Phase

0.0 miles

Learn More »

Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients

Metastatic breast cancer (MBC) is incurable, and the majority of patients succumb to their disease within 2 years of diagnosis. Patients with MBC usually receive treatment with endocrine or cytotoxic chemotherapeutic agents, and treatment decisions are generally guided by the hormone receptor and Human Epidermal Growth Factor Receptor 2-Negative status ...

Phase

0.0 miles

Learn More »

Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy

Metastatic Breast Cancer (MBC) patients from ten Italian Divisions of Medical Oncology, with histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1,8 and 15, every 4 weeks, will be enrolled ...

Phase N/A

0.0 miles

Learn More »

Overcoming Endocrine Resistance in Metastatic Breast Cancer

In presence of ER hypersensitivity even a small amount of ER may be sufficient for sustained growth signalling. On the other hand, ER disruption operated by fulvestrant is not complete, particularly in the initial phase of treatment. From phase III trials, indeed, The invertigators know that with the standard 250mg ...

Phase

0.0 miles

Learn More »

A Study to Evaluate Safety Efficacy Pharmacokinetics and Pharmacodynamics of Erdafitinib Plus JNJ-63723283 an Anti-PD-1 Monoclonal Antibody in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations

This open-label (all people know identity of intervention) and multicenter (when more than one hospital or medical school team work on a medical research study) study of erdafitinib plus JNJ-63723283 in participants with advanced urothelial cancer with selected fibroblast growth factor receptor (FGFR) gene alterations who have progressed on or ...

Phase

0.0 miles

Learn More »

Contemporary Clinical Management Of Acute Pulmonary Embolism

This is a prospective, non-interventional, multicenter study in patients with acute pulmonary embolism admitted to Cardiology, Emergency and Internal Medicine Departments in Italy. The aim of the study is to assess contemporary management strategies in patients with acute pulmonary embolism in terms of diagnosis, risk stratification, hospitalization and treatment in ...

Phase N/A

0.0 miles

Learn More »